Study: Vytorin Tops Lipitor in High-Risk Patients (Reuters)


Reuters - A combination medicine by Merck & Co.
and Schering-Plough Corp. was more effective in helping
high-risk patients achieve stringent, new lower cholesterol
goals than Pfizer Inc.'s top-selling Lipitor in a clinical
trial.

Read more...